Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
CCTG BL12
Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.
- NCT02033993 ↗
- Completed
- Canadian Cancer Trials Group
- Focused
We haven't built an HCP commentary report on CCTG BL12 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CCTG BL12 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients With Advanced Urothelial Cancer Progressing on or After a Platinum Containing Regimen.
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Urothelial Cancer
- Interventions
- Nab-Paclitaxel; Paclitaxel
- Arms
- Arm 1 · Active comparator
- Arm 2 · Active comparator
- Enrollment
- 199
- Primary outcomes
- Progression-Free Survival
- Sponsor
- Canadian Cancer Trials Group with Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Celgene
- Start
- Mar 11, 2014
- Primary completion
- May 3, 2018
- Results posted
- Yes
- Registry record
- NCT02033993 · updated Aug 22, 2023
Publications
linked from the registry- Sridhar SS, Blais N, Tran B, Reaume MN, North SA, Stockler MR, Chi KN, Fleshner NE, Liu G, Robinson JW, Mukherjee SD, Rahim Y, Winquist E, Booth CM, Nguyen NT, Beardsley EK, Alimohamed NS, McDonald GT, Ding K, Parulekar WR. Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial. JAMA Oncol. 2020 Nov 1;6(11):1751-1758. doi: 10.1001/jamaoncol.2020.3927. PubMed 32940628